Calcium Aspartate Anhydrous for Increasing Knee Cartilage Volumes in Arthritis Patients:
New Evidence

Calcium Aspartate Anhydrous for Increasing Knee Cartilage Volumes in Arthritis Patients

Shidong Liu, Shanghai Second Medical University. Xiaoyu Shi, Rui Jin Hospital and J.F. Tang, China Institute of Medical Engineering.

Introduction

Magnetic Resonance Imaging (MRI) was used to investigating structural changes to hyaline cartilage in arthritis patients using calcium aspartate anhydrous (CaJAA).

Aims and Objectives

To quantify femoral, tibial and patellar cartilage volume changes over a period of one year in patient volunteers using calcium aspartate anhydrous (CaJAA) to enhance Type II collagen production and to treat osteoarthritis (OA) and rheumatoid arthritis (RA).

Methods

Ninety-three patients (48RA, 450A) were selected for imaging following a clinical examination of their arthritis. They were then assigned to three groups: OA, RA and placebo. The OA group comprised 31 OA patients. Nineteen of them were male (age range 55-73, mean 63 years) and 12 were female (age range 54- 75, mean 64 years). The RA group had 31 RA patients. Fifteen were male (age range 52-69, mean 61 years) and 16 were female (age range 48- 71, mean 58 years). The placebo group had 17 RA patients and 14 OA patients. 13 were male (age range 51- 72, mean 62 years) and 18 were female (age range 50-73, mean 63 years).

Knee imaging was performed on a Siemens Impact clinical scanner (field strength l.OT) using a 3D gradient-echo imaging sequence with fat suppresion. Imaging parameters were TRlTE=50/11 (400 flip angle), allowing excitation of a 100mm slice block and generation of a series of 64 contiguous sagittal image slices each l.56mm thick. Phase encoding was limited to 192 steps, and zero-filling was implemented to display the images on a 256x256 matrix (voxel resolution 0.55xO.55xl.56mm). The total imaging time was just over ten minutes. Imaging was performed on each patient knee at entry into the study, and subsequently at n, and 52 weeks (n=8, 16 or 24 weeks).

Patients in the OA and RA group were given 1000mg of calcium aspartate anhydrous (CaIAA) three times a day for the period of one year. Patients in the placebo group received 1000mg powder that contains 5% calcium lactate pentahydrate three times a day for the same period.

Femoral, medial tibial, lateral tibial and patellar cartilage volumes were obtained by manual segmentation using a combination of inhouse software and commercial software (TOSCA, IBM). Qualitative progression was assessed by visual Inspection of3-D renditions using DX, IBM of the TOSCA segmentations.

Results

Qualitative assessments showed that all of the patient volunteers studied had cartilage lesions detectable by MRI. The number of compartments with cartilage lesions ranged from 2-4 affected compartments per individual (mean 3.3, median 3 for OA group, mean 3.4, median 4 for RA group, and mean 3.3, median 3 for Placebo group). Of the 93 individuals, 89 had cartilage lesions in the femoral condyle, 52 had lesions in the lateral tibial plateau; 46 had lesions in the medial tibial plateau, and 36 had lesions in the patella. In many cases each compartment had more than one distinct cartilage lesion, and lesions varied considerably in size.

Cartilage remodeling was evident in many of the patients in the OA and RA groups over the one-year study as demonstrated qualitatively by changes in the size and shape of the cartilage lesion. Both decreases and increases in cartilage lesion size were observed and shown in Table 1. 86.27% in the OA group and 76.41 % in the RA group had their cartilage lesion size reduced more or less during the year of using calcium aspartate anhydrous, as opposed to 16.5% in the placebo group. Only 2.94% and 3.77% in the OA and RA group respectively had their lesion size increased, vs. a total of 39.81% in the placebo group.




Level of Lesion Size Change



Significantl

Moderately

No Change

Moderately

Significantl

Total # of


y Reduced

Reduced

Increased

y Increased

Lesions

OA

27(26.47%)

61(59.80%)

11(10.78%)

3(2.94%)

0(0%)

102

RA

18(16.98%)

63(59.43%)

21(19.81%)

4(3.77%)

0(0%)

106

Placebo

2(1.94%)

15(14.56%)

45(43.69%)

32(31.07%)

9(8.74%)

103

Table I. Number of Cartilage Lesion Size Change for Different Groups





Change of Knee Cartilage Volume III



FEMUR

MEDTIB

LATTIB

PATELLA

TOTAL

OA-Male

254 126

6333

5738

6953

443 163

OA-Female

201 153

5335

6532

6249

381 198

RA-Male

213 145

6928

61 34

5661

399211

RA-Female

187 102

6239

52 36

4239

343 128

Placebo-Male

-68 103

-43 51

1540

2743

-69 131

Placebo-Female

-24 97

-425

-62 32

1837

-72 116

Quantitative measure of cartilage volume change showed that patients in the OA and RA groups had gained significant amount of cartilage.

Analysis of cartilage volume change in each compartment stratified for the three groups and different sex are shown in Table I

The cartilage volume increases in the OA and RA groups are statistically significant.

Conclusion

This study demonstrated that patients with osteoarthritis or arthritis gained back significant volume in the knee cartilage and the size of their cartilage lesions had reduced while using Calcium Aspartate Anhydrous

CLICK HERE To Learn More About The Uses Of Ezorb Calcium and How It Can Enrich Your Life

References

[1] Accuracy off at-suppressed 3-D spoiled gradient-echo FLASH MR imaging in the detection of patellofemoral articular cartilage abnormalities. Recht MP et al. Radiology, 1996 198:209-212

[2] In vivo reproducibility of three-dimensional cartilage volume and thickness measurements with MR imaging, Eckstein F et al. Am. J. Roentgenol., 1998 170:593-597.

[3] Longitudinal measurement of knee articular cartilage volume in osteoarthritis. Peterfy CG et aI., Radiology, 1998 209P:411.

[4] Diurnal variation in the femoral articular cartilage ofthe knee in young adult humans. Waterton IC et al., Magn. Res. Med., 2000.